These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 16159619)

  • 1. Fluticasone propionate plasma concentration and systemic effect: effect of delivery device and duration of administration.
    Whelan GJ; Blumer JL; Martin RJ; Szefler SJ;
    J Allergy Clin Immunol; 2005 Sep; 116(3):525-30. PubMed ID: 16159619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate.
    Wardlaw A; Larivee P; Eller J; Cockcroft DW; Ghaly L; Harris AG
    Ann Allergy Asthma Immunol; 2004 Jul; 93(1):49-55. PubMed ID: 15281471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
    Murphy K; Noonan M; Silkoff PE; Uryniak T
    Clin Ther; 2007 Jun; 29(6):1013-26. PubMed ID: 17692718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a 12-week therapy with a new formulation of fluticasone propionate at doses of 125 and 250 μg administered through a new generation cyclohaler twice daily, in comparison to fluticasone propionate 500 μg dry powder inhaler twice daily in patients with moderate asthma.
    Kupryś-Lipińska I; Tworek D; Vanderbist F; Bocheńska-Marciniak M; Kuna P
    Pneumonol Alergol Pol; 2013; 81(6):527-36. PubMed ID: 24142782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in patients with mild-to-moderate asthma.
    Falcoz C; Horton J; Mackie AE; Harding SM; Daley-Yates PT
    Clin Pharmacokinet; 2000; 39 Suppl 1():31-7. PubMed ID: 11140431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of fluticasone metered-dose inhaler and dry powder inhaler for pediatric asthma.
    Miyahara H; Korematsu S; Nagakura T; Izumi T
    Pediatr Int; 2008 Feb; 50(1):103-8. PubMed ID: 18279216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of mometasone furoate dry powder inhaler and fluticasone propionate dry powder inhaler in patients with moderate to severe persistent asthma requiring high-dose inhaled corticosteroid therapy: findings from a noninferiority trial.
    Harnest U; Price D; Howes T; Sussman G
    J Asthma; 2008 Apr; 45(3):215-20. PubMed ID: 18415829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma?
    Koenig SM; Murray JJ; Wolfe J; Andersen L; Yancey S; Prillaman B; Stauffer J; Dorinsky P
    Respir Med; 2008 May; 102(5):665-73. PubMed ID: 18328683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent use of metered-dose and dry powder inhalers by children with persistent asthma does not adversely affect spacer/inhaler technique.
    Chan DS; Callahan CW; Hatch-Pigott VB; Lawless A; Proffitt HL; Manning NE; Schweikert MP
    Ann Pharmacother; 2006 Oct; 40(10):1743-6. PubMed ID: 16968822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects.
    Harrison TW; Tattersfield AE
    Thorax; 2003 Mar; 58(3):258-60. PubMed ID: 12612308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fluticasone propionate in children and infants with asthma].
    Marchac V; Foussier V; Devillier P; Le Bourgeois M; Polak M
    Arch Pediatr; 2007 Apr; 14(4):376-87. PubMed ID: 17289359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient perceptions of an inhaled asthma medication administered as an inhalation powder via the Diskus or as an inhalation aerosol via a metered-dose inhaler.
    Sheth K; Bernstein JA; Lincourt WR; Merchant KK; Edwards LD; Crim CC; Dorinsky PM
    Ann Allergy Asthma Immunol; 2003 Jul; 91(1):55-60. PubMed ID: 12877450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses.
    Affrime MB; Kosoglou T; Thonoor CM; Flannery BE; Herron JM
    Chest; 2000 Dec; 118(6):1538-46. PubMed ID: 11115437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of fluticasone propionate multidose, inhalation-driven, novel, dry powder inhaler versus a prevailing dry powder inhaler and a metered-dose inhaler.
    Gillespie M; Song S; Steinfeld J
    Allergy Asthma Proc; 2015; 36(5):365-71. PubMed ID: 26314817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic Comparison of a Unit Dose Dry Powder Inhaler with a Multidose Dry Powder Inhaler for Delivery of Fluticasone Furoate.
    Mehta R; Moore A; Riddell K; Joshi S; Chan R
    J Aerosol Med Pulm Drug Deliv; 2017 Oct; 30(5):332-338. PubMed ID: 28463040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
    Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
    Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Itraconazole comedication increases systemic levels of inhaled fluticasone in lung transplant recipients.
    Naef R; Schmid C; Hofer M; Minder S; Speich R; Boehler A
    Respiration; 2007; 74(4):418-22. PubMed ID: 17003527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma.
    Koopmans JG; Lutter R; Jansen HM; van der Zee JS
    Thorax; 2006 Apr; 61(4):306-12. PubMed ID: 16449264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new formulation of fluticasone propionate/salmeterol in a metered-dose inhaler (MDI HFA) allows for the reduction of a daily dose of corticosteroid and provides optimal asthma control - A randomized, multi-center, non-inferiority, phase IV clinical study.
    Kupczyk M; Majak P; Kuna P; Asankowicz-Bargiel B; Barańska E; Dobek R; Garbicz S; Jerzyńska J; Latos A; Machowiak W; Majorek-Olechowska B; Olech-Cudzik A; Poziomkowska-Gęsicka I; Rulewicz-Warniełło M; Świderska A; Tarnowski M; Kopyto P
    Respir Med; 2021 Jan; 176():106274. PubMed ID: 33276251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.